1 – 10 of 33
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2018
- Updated European Association of Urology Guidelines : Recommendations for the Treatment of First-line Metastatic Clear Cell Renal Cancer
- Re : Is Preoperative Assessment and Treatment of Asymptomatic Bacteriuria Necessary for Reducing the Risk of Postoperative Symptomatic Urinary Tract Infection After Urologic Surgical Procedures?
- Association Between Lead Time and Prostate Cancer Grade : Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening
- Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer : Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial
- 2017
- Should we Refrain from Performing Oophorectomy in Conjunction with Radical Cystectomy for Bladder Cancer?
- Association of Radical Local Treatment with Mortality in Men with Very High-risk Prostate Cancer : A Semiecologic, Nationwide, Population-based Study
- Prostate Cancer Death After Radiotherapy or Radical Prostatectomy : A Nationwide Population-based Observational Study
- Port-site Metastases After Robot-assisted Radical Cystectomy : Is There a Publication Bias?
- Re : Thomas Powles, Robert A. Huddart, Tony Elliott, et al. Phase III, Double-blind, Randomized Trial that Compared Maintenance Lapatinib versus Placebo after First-line Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 1/2-positive Metastatic Bladder Cancer. J Clin Oncol 2017;35:48-55. Knowing HER2 Status is Not Enough: A Molecular Subtype Approach to Bladder
- Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy